{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:26:18Z","timestamp":1785403578632,"version":"3.56.0"},"reference-count":19,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,12,18]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine how soon after commencement of the seasonal influenza vaccination programme, the AusVaxSafety active vaccine safety surveillance system, currently in use across Australia, would have detected a safety signal had it been operating in 2010 when there was an unprecedented number of febrile seizures in young children associated with one specific influenza vaccine brand, Fluvax (CSL Biotherapies).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Simulation study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Western Australian vaccine influenza coverage and adverse event surveillance data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome measures<\/jats:title><jats:p>Simulated solicited responses from caregivers who would have received an SMS survey about adverse events experienced following seasonal influenza vaccination of their children aged 6 months to &lt;5 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>None.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We estimated a &gt;90% probability of a safety signal being detected by AusVaxSafety based on solicited reports for either fever or medical attendance at or before the week ending 28 March 2010, 3 weeks after the start of vaccine distribution. Suspension of the national paediatric influenza vaccination programme as a result of the passive adverse events surveillance operating at the time did not occur until 23 April 2010.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Active vaccine safety surveillance leading to rapid detection of a safety signal would likely have resulted in earlier suspension of Fluvax from the vaccination programme, prevention of many febrile convulsions and maintenance of public confidence in influenza vaccination for young children.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2019-031851","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T08:49:23Z","timestamp":1583138963000},"page":"e031851","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Timeliness of signal detection for adverse events following influenza vaccination in young children: a simulation case study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-7697","authenticated-orcid":false,"given":"Peter","family":"Jacoby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Damon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen","family":"Fathima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Pillsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Durrheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Leeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,1]]},"reference":[{"key":"2024052015123900000_10.2.e031851.1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.2014.866895","article-title":"Active surveillance for adverse events following immunization","volume":"13","author":"Crawford","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"2024052015123900000_10.2.e031851.2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/inthealth\/ihx019","article-title":"Participant-centred active surveillance of adverse events following immunisation: a narrative review","volume":"9","author":"Cashman","year":"2017","journal-title":"Int Health"},{"key":"2024052015123900000_10.2.e031851.3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.5694\/j.1326-5377.2010.tb04029.x","article-title":"Febrile convulsions after 2010 seasonal trivalent influenza vaccine: implications for vaccine safety surveillance in Australia","volume":"193","author":"Gold","year":"2010","journal-title":"Med J Aust"},{"key":"2024052015123900000_10.2.e031851.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.05.054"},{"key":"2024052015123900000_10.2.e031851.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2010-000016","article-title":"Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine","volume":"1","author":"Armstrong","year":"2011","journal-title":"BMJ Open"},{"key":"2024052015123900000_10.2.e031851.6","unstructured":"Horvath J . Review of the management of adverse events associated with Panvax and Fluvax. Department of Health and Ageing, 2011."},{"key":"2024052015123900000_10.2.e031851.7","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0320","article-title":"Febrile seizure risk after vaccination in children 6 to 23 months","volume":"138","author":"Duffy","year":"2016","journal-title":"Pediatrics"},{"key":"2024052015123900000_10.2.e031851.8","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1016\/j.vaccine.2014.05.055","article-title":"The impact of pandemic A(H1N1)pdm09 influenza and vaccine-associated adverse events on parental attitudes and influenza vaccine uptake in young children","volume":"32","author":"Blyth","year":"2014","journal-title":"Vaccine"},{"key":"2024052015123900000_10.2.e031851.9","doi-asserted-by":"publisher","DOI":"10.5694\/mja13.11166"},{"key":"2024052015123900000_10.2.e031851.10","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1016\/j.vaccine.2014.07.061","article-title":"Vaxtracker: active on-line surveillance for adverse events following inactivated influenza vaccine in children","volume":"32","author":"Cashman","year":"2014","journal-title":"Vaccine"},{"key":"2024052015123900000_10.2.e031851.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023263","article-title":"Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia","volume":"8","author":"Pillsbury","year":"2018","journal-title":"BMJ Open"},{"key":"2024052015123900000_10.2.e031851.12","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1016\/j.vaccine.2017.10.091","article-title":"Active SMS-based influenza vaccine safety surveillance in Australian children","volume":"35","author":"Pillsbury","year":"2017","journal-title":"Vaccine"},{"key":"2024052015123900000_10.2.e031851.13","doi-asserted-by":"crossref","unstructured":"Pillsbury A , Cashman P , Leeb A , et al . Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015. Euro Surveill 2015;20.doi:10.2807\/1560-7917.ES.2015.20.43.30050","DOI":"10.2807\/1560-7917.ES.2015.20.43.30050"},{"key":"2024052015123900000_10.2.e031851.14","doi-asserted-by":"publisher","DOI":"10.1177\/096228020301200205"},{"key":"2024052015123900000_10.2.e031851.15","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2015.20.24.21159","article-title":"Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children","volume":"20","author":"Li-Kim-Moy","year":"2015","journal-title":"Euro Surveill"},{"key":"2024052015123900000_10.2.e031851.16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/irv.12107","article-title":"Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents","volume":"7","author":"Lambert","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"2024052015123900000_10.2.e031851.17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1750-2659.2009.00108.x","article-title":"Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children","volume":"3","author":"Nolan","year":"2009","journal-title":"Influenza Other Respir Viruses"},{"key":"2024052015123900000_10.2.e031851.18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/INF.0b013e31823d5303","article-title":"Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia","volume":"31","author":"Wood","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2024052015123900000_10.2.e031851.19","unstructured":"Child's death linked to flu vaccine. Available: https:\/\/www.smh.com.au\/national\/childs-death-linked-to-flu-vaccine-20100426-tm6t.html"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-031851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:20:45Z","timestamp":1716243645000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-031851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,3,1]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/bmjopen-2019-031851"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-031851","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}